Director Perez purchases 10,000 shares at $7.63 amid cluster of 4 other insider buys in 14 days; stock down 40.7% in 90 days.
Perez David Brian, a director at NeoGenomics, acquired 10,000 shares at $7.63 on 2025-05-05 in his first reported open-market purchase at this company (0 to 10,000 shares post-transaction). This buy occurs within a cluster pattern: 4 other insiders also purchased shares within the past 14 days. The context is material: NeoGenomics stock has fallen -40.7% over the past 90 days and is -57.0% from its 52-week high of $18.61, despite the company posting +11.6% annual revenue growth to $168.0M in the latest quarter. However, the company remains unprofitable, with a full-year net income of -$25.9M. The concurrent buying activity by multiple insiders at a significantly depressed price level merits observation, though the broader deterioration in fundamentals and sustained unprofitability warrant caution.